Copyright Reports & Markets. All rights reserved.

Global Long-acting ESAs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Long-acting ESAs Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Darbepoetin Alfa
    • 1.3.3 Methoxy Polyethylene Glycol-Epoetin Beta
    • 1.3.4 Pegmolesatide
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Long-acting ESAs Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Renal Anemia
    • 1.4.3 Cancer
    • 1.4.4 Other
  • 1.5 Global Long-acting ESAs Market Size & Forecast
    • 1.5.1 Global Long-acting ESAs Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Long-acting ESAs Sales Quantity (2021-2032)
    • 1.5.3 Global Long-acting ESAs Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Kyowa Kirin
    • 2.1.1 Kyowa Kirin Details
    • 2.1.2 Kyowa Kirin Major Business
    • 2.1.3 Kyowa Kirin Long-acting ESAs Product and Services
    • 2.1.4 Kyowa Kirin Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Kyowa Kirin Recent Developments/Updates
  • 2.2 Amgen
    • 2.2.1 Amgen Details
    • 2.2.2 Amgen Major Business
    • 2.2.3 Amgen Long-acting ESAs Product and Services
    • 2.2.4 Amgen Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Amgen Recent Developments/Updates
  • 2.3 Dr. Reddy's Laboratories
    • 2.3.1 Dr. Reddy's Laboratories Details
    • 2.3.2 Dr. Reddy's Laboratories Major Business
    • 2.3.3 Dr. Reddy's Laboratories Long-acting ESAs Product and Services
    • 2.3.4 Dr. Reddy's Laboratories Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Dr. Reddy's Laboratories Recent Developments/Updates
  • 2.4 Roche
    • 2.4.1 Roche Details
    • 2.4.2 Roche Major Business
    • 2.4.3 Roche Long-acting ESAs Product and Services
    • 2.4.4 Roche Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Roche Recent Developments/Updates
  • 2.5 Hansoh Pharma
    • 2.5.1 Hansoh Pharma Details
    • 2.5.2 Hansoh Pharma Major Business
    • 2.5.3 Hansoh Pharma Long-acting ESAs Product and Services
    • 2.5.4 Hansoh Pharma Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Hansoh Pharma Recent Developments/Updates
  • 2.6 Cipla
    • 2.6.1 Cipla Details
    • 2.6.2 Cipla Major Business
    • 2.6.3 Cipla Long-acting ESAs Product and Services
    • 2.6.4 Cipla Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Cipla Recent Developments/Updates
  • 2.7 Sanwa Kagaku Kenkyusho
    • 2.7.1 Sanwa Kagaku Kenkyusho Details
    • 2.7.2 Sanwa Kagaku Kenkyusho Major Business
    • 2.7.3 Sanwa Kagaku Kenkyusho Long-acting ESAs Product and Services
    • 2.7.4 Sanwa Kagaku Kenkyusho Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Sanwa Kagaku Kenkyusho Recent Developments/Updates
  • 2.8 Kissei Pharmaceutical
    • 2.8.1 Kissei Pharmaceutical Details
    • 2.8.2 Kissei Pharmaceutical Major Business
    • 2.8.3 Kissei Pharmaceutical Long-acting ESAs Product and Services
    • 2.8.4 Kissei Pharmaceutical Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Kissei Pharmaceutical Recent Developments/Updates
  • 2.9 Kyowa Hakko Kirin
    • 2.9.1 Kyowa Hakko Kirin Details
    • 2.9.2 Kyowa Hakko Kirin Major Business
    • 2.9.3 Kyowa Hakko Kirin Long-acting ESAs Product and Services
    • 2.9.4 Kyowa Hakko Kirin Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Kyowa Hakko Kirin Recent Developments/Updates
  • 2.10 Torrent Pharmaceuticals
    • 2.10.1 Torrent Pharmaceuticals Details
    • 2.10.2 Torrent Pharmaceuticals Major Business
    • 2.10.3 Torrent Pharmaceuticals Long-acting ESAs Product and Services
    • 2.10.4 Torrent Pharmaceuticals Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Torrent Pharmaceuticals Recent Developments/Updates
  • 2.11 CKD Pharma
    • 2.11.1 CKD Pharma Details
    • 2.11.2 CKD Pharma Major Business
    • 2.11.3 CKD Pharma Long-acting ESAs Product and Services
    • 2.11.4 CKD Pharma Long-acting ESAs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 CKD Pharma Recent Developments/Updates

3 Competitive Environment: Long-acting ESAs by Manufacturer

  • 3.1 Global Long-acting ESAs Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Long-acting ESAs Revenue by Manufacturer (2021-2026)
  • 3.3 Global Long-acting ESAs Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Long-acting ESAs by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Long-acting ESAs Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Long-acting ESAs Manufacturer Market Share in 2025
  • 3.5 Long-acting ESAs Market: Overall Company Footprint Analysis
    • 3.5.1 Long-acting ESAs Market: Region Footprint
    • 3.5.2 Long-acting ESAs Market: Company Product Type Footprint
    • 3.5.3 Long-acting ESAs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Long-acting ESAs Market Size by Region
    • 4.1.1 Global Long-acting ESAs Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Long-acting ESAs Consumption Value by Region (2021-2032)
    • 4.1.3 Global Long-acting ESAs Average Price by Region (2021-2032)
  • 4.2 North America Long-acting ESAs Consumption Value (2021-2032)
  • 4.3 Europe Long-acting ESAs Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Long-acting ESAs Consumption Value (2021-2032)
  • 4.5 South America Long-acting ESAs Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Long-acting ESAs Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Long-acting ESAs Sales Quantity by Type (2021-2032)
  • 5.2 Global Long-acting ESAs Consumption Value by Type (2021-2032)
  • 5.3 Global Long-acting ESAs Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Long-acting ESAs Sales Quantity by Application (2021-2032)
  • 6.2 Global Long-acting ESAs Consumption Value by Application (2021-2032)
  • 6.3 Global Long-acting ESAs Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Long-acting ESAs Sales Quantity by Type (2021-2032)
  • 7.2 North America Long-acting ESAs Sales Quantity by Application (2021-2032)
  • 7.3 North America Long-acting ESAs Market Size by Country
    • 7.3.1 North America Long-acting ESAs Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Long-acting ESAs Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Long-acting ESAs Sales Quantity by Type (2021-2032)
  • 8.2 Europe Long-acting ESAs Sales Quantity by Application (2021-2032)
  • 8.3 Europe Long-acting ESAs Market Size by Country
    • 8.3.1 Europe Long-acting ESAs Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Long-acting ESAs Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Long-acting ESAs Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Long-acting ESAs Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Long-acting ESAs Market Size by Region
    • 9.3.1 Asia-Pacific Long-acting ESAs Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Long-acting ESAs Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Long-acting ESAs Sales Quantity by Type (2021-2032)
  • 10.2 South America Long-acting ESAs Sales Quantity by Application (2021-2032)
  • 10.3 South America Long-acting ESAs Market Size by Country
    • 10.3.1 South America Long-acting ESAs Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Long-acting ESAs Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Long-acting ESAs Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Long-acting ESAs Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Long-acting ESAs Market Size by Country
    • 11.3.1 Middle East & Africa Long-acting ESAs Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Long-acting ESAs Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Long-acting ESAs Market Drivers
  • 12.2 Long-acting ESAs Market Restraints
  • 12.3 Long-acting ESAs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Long-acting ESAs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Long-acting ESAs
  • 13.3 Long-acting ESAs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Long-acting ESAs Typical Distributors
  • 14.3 Long-acting ESAs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Long-acting ESAs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Long-acting erythropoiesis-stimulating agents (ESAs) are medications designed to stimulate red blood cell production over an extended period, reducing the frequency of administration compared to traditional ESAs. These drugs, such as darbepoetin alfa and methoxy polyethylene glycol-epoetin beta, are modified to have a prolonged half-life, allowing for less frequent dosing—typically once every two to four weeks—while maintaining their effectiveness in treating anemia. Long-acting ESAs are commonly used to treat anemia related to chronic kidney disease (CKD) and chemotherapy-induced anemia.
    This report is a detailed and comprehensive analysis for global Long-acting ESAs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Long-acting ESAs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Long-acting ESAs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Long-acting ESAs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Long-acting ESAs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Long-acting ESAs
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Long-acting ESAs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Kyowa Kirin, Amgen, Dr. Reddy's Laboratories, Roche, Hansoh Pharma, Cipla, Sanwa Kagaku Kenkyusho, Kissei Pharmaceutical, Kyowa Hakko Kirin, Torrent Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Long-acting ESAs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Darbepoetin Alfa
    Methoxy Polyethylene Glycol-Epoetin Beta
    Pegmolesatide
    Market segment by Application
    Renal Anemia
    Cancer
    Other
    Major players covered
    Kyowa Kirin
    Amgen
    Dr. Reddy's Laboratories
    Roche
    Hansoh Pharma
    Cipla
    Sanwa Kagaku Kenkyusho
    Kissei Pharmaceutical
    Kyowa Hakko Kirin
    Torrent Pharmaceuticals
    CKD Pharma
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Long-acting ESAs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Long-acting ESAs, with price, sales quantity, revenue, and global market share of Long-acting ESAs from 2021 to 2026.
    Chapter 3, the Long-acting ESAs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Long-acting ESAs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Long-acting ESAs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting ESAs.
    Chapter 14 and 15, to describe Long-acting ESAs sales channel, distributors, customers, research findings and conclusion.

    Buy now